CAC 40
8 047,34 +30,69 (+0,38 %) Euro Stoxx 50
4 980,63 +41,62 (+0,84 %) Dow Jones
38 085,80 -375,12 (-0,98 %) EUR/USD
1,0734 +0,0001 (+0,01 %) Gold future
2 358,90 +16,40 (+0,70 %) Bitcoin EUR
59 781,41 +290,30 (+0,49 %)
Royalty Pharma plc (RPRX)
Échanges après Bourse :
Royalty Pharma plc
110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO | S.O. | S.O. | 1965 |
| Mr. Terrance P. Coyne | Executive VP & CFO | 4,35M | S.O. | S.O. |
| Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 4,35M | S.O. | 1960 |
| Mr. Christopher Hite | Vice Chairman & Executive VP | 4,35M | S.O. | 1967 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive VP and Head of Research & Investments | 4,35M | S.O. | S.O. |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | S.O. | S.O. | S.O. |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments | S.O. | S.O. | S.O. |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer | S.O. | S.O. | S.O. |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 3,4M | S.O. | 1970 |
| Mr. George Grofik C.F.A., CPA | Senior VP and Head of Investor Relations & Communications | S.O. | S.O. | S.O. |
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Royalty Pharma plc en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 5; Société : 5; Droits des actionnaires : 6; Compensation : 3.
